Please assess the completion status of the following clinical trial:

Trial Title: Advancing Tobacco Use Treatment for African American Smokers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Self-identified African American~* Smokes ≥ 1 cigarette per day (cpd)~* Smoke on ≥ 25 days of the past 30 days~* Functioning telephone~* Interested in quitting smoking~* Interested in taking 3 months of varenicline~* Willing to complete all study visits~Exclusion Criteria:~* Renal impairment~* Evidence or history of clinically significant allergic reactions to varenicline~* A cardiovascular event in the past month~* History of alcohol or drug dependence in the past year~* Major depressive disorder in the last year requiring treatment~* History of panic disorder, psychosis, bipolar disorder, or eating disorders~* Use of tobacco products other than cigarettes in past 30 days~* Use of pharmacotherapy in the month prior to enrollment, including prior use of varenicline~* Pregnant, contemplating getting pregnant, or breastfeeding~* Plans to move from Kansas City during the treatment and follow-up phase~* Another household member enrolled in the study~* Evidence of current severe major depressive disorder or suicidal ideation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Chantix (varenicline) (Type: EXPERIMENTAL): Participants will receive 1mg pills to take twice a day for 12 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Participants will receive a placebo pill to take twice a day for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).